PJP

Featured

Pharmaceutical ETFs: Drug Companies Roar Back

By Tom LydonNovember 16, 2010

Featured

Why Health Care ETFs May Be In the Clear

By Tom LydonNovember 10, 2010

Featured

Pharma ETFs Find New Avenues of Growth

By Tom LydonOctober 8, 2010

Equity ETFs

Health Care ETFs: Next Up, Emerging Markets

By Tom LydonAugust 30, 2010

Featured

ETFs for a Changing Pharma Landscape

By Tom LydonAugust 5, 2010

Featured

The Bulls May Prevail: Pharmaceutical ETFs

By Tom LydonMay 13, 2010

Featured

Health Care Reform ETF Winners and Losers

By Tom LydonApril 5, 2010

Featured

4 ETFs for an Uncertain Future

By Tom LydonDecember 31, 2009

Featured

Emerging Markets: The Next Big Driver of Pharmaceutical, Biotech ETFs?

By Tom LydonDecember 15, 2009

Featured

Stocks, ETFs Move Higher as Trade Gap Narrows

By Tom LydonDecember 10, 2009

Featured

ETFs to Play Obama’s New Policies

By Tom LydonNovember 13, 2009

Featured

How Health Care Overhaul Affects ETFs

By Tom LydonOctober 14, 2009

Featured

How the Race for a Cancer Drug Could Help Pharmaceutical ETFs

By Tom LydonSeptember 7, 2009

Featured

Pharmaceuticals: How Obama Deal and New Approach Could Refresh ETFs

By Tom LydonJune 22, 2009

Featured

4 Reasons to Watch Pharmaceutical ETFs This Year

By Tom LydonJanuary 9, 2009

Featured

Pharmaceutical ETFs Ailing as Consumers Trim Costs

By Tom LydonOctober 22, 2008

Featured

Success Of Cancer Vaccines Could Have Pharm ETFs Feeling Good

By Tom LydonAugust 23, 2008